Omalizumab, a humanized monoclonal antibody that binds the CH3 domain near the binding site for the high affinity type-I IgE Fc receptors of human IgE, can neutralize free IgE and inhibit the IgE allergic pathway [1]. The current indications for treatment with omalizumab are limited to severe persistent allergic asthma and chronic spontaneous urticaria (CSU) when it is not controlled by conventional anti-H1 treatment at the maximum dosage. In recent years, several studies [1] have shown that omalizumab is effective in a large number of IgE-mediated and non-IgE-mediated disorders, indicating that omalizumab treatment acts on many levels and not only on immunoglobulins
Aruanno, A., Chini, R., Nucera, E., Efficacy of omalizumab in reducing latex allergy, <<POSTEPY DERMATOLOGII I ALERGOLOGII>>, 2021; 38 (5): 921-923. [doi:10.5114/ada.2021.110072] [http://hdl.handle.net/10807/200460]
Efficacy of omalizumab in reducing latex allergy
Nucera, Eleonora
2021
Abstract
Omalizumab, a humanized monoclonal antibody that binds the CH3 domain near the binding site for the high affinity type-I IgE Fc receptors of human IgE, can neutralize free IgE and inhibit the IgE allergic pathway [1]. The current indications for treatment with omalizumab are limited to severe persistent allergic asthma and chronic spontaneous urticaria (CSU) when it is not controlled by conventional anti-H1 treatment at the maximum dosage. In recent years, several studies [1] have shown that omalizumab is effective in a large number of IgE-mediated and non-IgE-mediated disorders, indicating that omalizumab treatment acts on many levels and not only on immunoglobulins
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
